RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $70 from $60 and keeps an Outperform rating on the shares. Following the firm’s opportunity to catch up with Apogee’s senior management on the latest updates to their clinical programs and developments in the AD – atopic dermatitis – space, RBC notes that its discussion has reaffirmed its confidence that the upcoming AD readouts should look favorable, the analyst tells investors in a research note. With timeline acceleration and the space continuing to grow, Apogee’s ‘777 and future combos can be poised to drive meaningful revenue opportunity, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy
- Apogee Therapeutics initiated with a Buy at Craig-Hallum
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know
- Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis